Morningstar

Zoetis Inc Class A ZTS

Stock XNYS Rating as of Nov 12, 2026

News

Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
Business Wire Nov 11, 2026, 12:30:00 PM
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
Business Wire Nov 10, 2026, 12:30:00 PM
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
Business Wire Nov 5, 2026, 12:00:00 PM
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Business Wire Oct 20, 2026, 8:42:00 PM
Zoetis Appoints Iris Knobloch to its Board of Directors
Business Wire Oct 13, 2026, 11:30:00 AM
Zoetis Declares Fourth Quarter 2026 Dividend
Business Wire Oct 8, 2026, 8:15:00 PM
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
Business Wire Oct 6, 2026, 11:30:00 AM
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Business Wire Sep 24, 2026, 11:30:00 AM
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire Sep 2, 2026, 11:30:00 AM
Zoetis Gets FDA Emergency-Use Approval for Screwworm in Dogs
Global News Select Aug 13, 2026, 8:08:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.